Beneficial Ownership Report · SCHEDULE 13D/A
Definitive Healthcare Corp.
DHNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13D/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Definitive Healthcare Corp.
- Company CIK
- 0001861795
- Street
- 492 Old Connecticut Path
- Street (continued)
- Suite 401
- City
- Framingham
- State / country code
- MA
- Postal code
- 01701
Statement details
- Amendment number
- 1
- Security class
- Class A Common Stock, $0.001 par value
- Event date
- 09/29/2026
Authorized notification person 1
- Name
- Neil Crawford
- Phone
- 617-951-9488
- Street
- Advent International, L.P.
- Street (continued)
- Prudential Tower, 800 Boylston Street
- City
- Boston
- State / country code
- MA
- Postal code
- 02199
Reporting person 1
- Name
- Advent International, L.P.
- Reporting person CIK
- 0001034196
- No reporting person CIK indication
- N
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- b
- Source of funds code
- OO
- Aggregate amount owned
- 62,493,676.00
- Percent of class
- 58.54
- Sole voting power
- 0.00
- Shared voting power
- 62,493,676.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 62,493,676.00
- Comments
- The reported percentage is calculated based on 106,744,713 shares of Class A Common Stock ("Common Stock") outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on August 10, 2026.
Reporting person 2
- Name
- Advent International GP, LLC
- No reporting person CIK indication
- Y
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- b
- Source of funds code
- OO
- Aggregate amount owned
- 62,493,676.00
- Percent of class
- 58.54
- Sole voting power
- 0.00
- Shared voting power
- 62,493,676.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 62,493,676.00
- Comments
- The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.
Reporting person 3
- Name
- Advent International GPE IX Limited Partnership
- No reporting person CIK indication
- Y
- Citizenship / organization
- E9
- Reporting person type
- PN
- Group designation
- b
- Source of funds code
- OO
- Aggregate amount owned
- 16,955,510.00
- Percent of class
- 15.88
- Sole voting power
- 16,955,510.00
- Shared voting power
- 0.00
- Sole dispositive power
- 16,955,510.00
- Shared dispositive power
- 0.00
- Comments
- The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.
Reporting person 4
- Name
- Advent International GPE IX-H Limited Partnership
- No reporting person CIK indication
- Y
- Citizenship / organization
- E9
- Reporting person type
- PN
- Group designation
- b
- Source of funds code
- OO
- Aggregate amount owned
- 5,428,915.00
- Percent of class
- 5.09
- Sole voting power
- 5,428,915.00
- Shared voting power
- 0.00
- Sole dispositive power
- 5,428,915.00
- Shared dispositive power
- 0.00
- Comments
- The reported percentage is calculated based on 106,744,713 shares of Common Stock outstanding as of August 6, 2026, as reported on the Issuer's 10-Q filed with the SEC on August 10, 2026.
Item 1
Issuer
Definitive Healthcare Corp.
Security title
Class A Common Stock, $0.001 par value
Principal address
Comment
The following constitutes Amendment No. 1 ("Amendment No. 1") to the Schedule 13D filed by the undersigned with the SEC on September 2, 2026 (the "Original Schedule 13D" and, as amended, the "Schedule 13D"). Except as set forth herein, the Schedule 13D remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D.
Item 4
Purpose of transaction
Item 4 of the Schedule 13D is hereby amended and supplemented to insert the following at the end thereof: Confidentiality Agreement On September 29, 2026, Advent LP entered into a confidentiality agreement (the "NDA") with the Issuer. The NDA provides that Advent LP generally will not disclose confidential information to any other person, except to its representatives and Mr. Krantz, other third parties with respect to which the Issuer provides prior written approval and potential funding sources with respect to which the Issuer provides written approval, among others, and will not use confidential information except for the purpose of considering, evaluating and negotiating a transaction with the Issuer. The NDA also includes a 12-month non-solicitation provision with respect to the Issuer's executive officers and a 12-month standstill provision pursuant to which Advent LP agreed not to make certain acquisitions of securities or assets of the Issuer, join or participate in a "group" formed after the date of the NDA, seek additional representation on the Issuer's board of directors or advise or influence any person with respect to the voting of any securities of the Issuer, in each case without the prior written consent of the Issuer and subject to certain exceptions. In accordance with the NDA, Advent LP intends to continue to engage with the Special Committee and third parties, including Mr. Krantz, regarding a transaction with the Issuer. References to the NDA do not purport to be complete and are qualified in their entirety by reference to the confidentiality agreement, a copy of which is attached hereto as Exhibit 99.6, and incorporated herein by reference in its entirety.
Item 5
Transactions
The Reporting Persons have not effected any transactions in Common Stock since the filing of the Original Schedule 13D.
Item 6
Contracts and arrangements
Item 6 of the Schedule 13D is hereby amended and supplemented to incorporate by reference at the end thereof, the information set forth in Item 4 of this Amendment No. 1.
Item 7
Filed exhibits
Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.6 Confidentiality Agreement, dated September 29, 2026.
Signature comments
Each of Advent International GPE IX Limited Partnership and Advent International GPE IX-H Limited Partnership, By: GPE IX GP Limited Partnership, their General Partner, By: Advent International GPE IX, LLC, its General Partner, By: Advent International, L.P., its Manager, By: Advent International GP, LLC, its General Partner.
Signature 1
- Reporting person
- Advent International, L.P.
- Signed
- /s/ Neil Crawford
- Title
- Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its General Partner
- Date
- 10/01/2026
Signature 2
- Reporting person
- Advent International GP, LLC
- Signed
- /s/ Neil Crawford
- Title
- Neil Crawford / Senior Director, Fund Administration
- Date
- 10/01/2026
Signature 3
- Reporting person
- Advent International GPE IX Limited Partnership
- Signed
- /s/ Neil Crawford
- Title
- Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its indirect General Partner
- Date
- 10/01/2026
Signature 4
- Reporting person
- Advent International GPE IX-H Limited Partnership
- Signed
- /s/ Neil Crawford
- Title
- Neil Crawford / Senior Director, Fund Administration of Advent International GP, LLC, its indirect General Partner
- Date
- 10/01/2026
Filed exhibits
- EXHIBIT 99.6 ↗ef20083031_ex99-6.htm
Company context
Definitive Healthcare is a data and analytics company focused on the business side of healthcare. The healthcare market is complex - our data makes it clearer. We cut through the noise to deliver the insights that healthcare organizations and companies need to make smarter, faster, more strategic decisions. Because when our customers succeed, healthcare gets better for everyone. Learn more at definitivehc.com.